Home » Stocks » ORTX

Orchard Therapeutics PLC (ORTX)

Stock Price: $4.20 USD -0.09 (-2.10%)
Updated Oct 28, 2020 12:05 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 409.82M
Revenue (ttm) 3.11M
Net Income (ttm) -180.22M
Shares Out 97.58M
EPS (ttm) -1.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $4.20
Previous Close $4.29
Change ($) -0.09
Change (%) -2.10%
Day's Open 4.25
Day's Range 4.07 - 4.26
Day's Volume 236,835
52-Week Range 3.83 - 15.93

More Stats

Market Cap 409.82M
Enterprise Value 224.88M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 97.58M
Float 84.01M
EPS (basic) n/a
EPS (diluted) -1.83
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.28M
Short Ratio 4.68
Short % of Float 3.90%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 131.78
PB Ratio 1.94
Revenue 3.11M
Operating Income n/a
Net Income -180.22M
Free Cash Flow n/a
Net Cash 184.94M
Net Cash / Share 1.90
Gross Margin 54.92%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -27.76%
ROE -60.26%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(245.24% upside)
Current: $4.20
Target: 14.50
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth21.05%---
Gross Profit1.711.65--
Operating Income-173-235-38.51-19.20
Net Income-163-230-39.74-19.09
Shares Outstanding93.2422.568.877.10
Earnings Per Share-1.75-10.22-4.48-2.69
Operating Cash Flow-166-97.54-32.49-14.57
Capital Expenditures-4.37-4.03-1.56-0.19
Free Cash Flow-170-102-34.05-14.76
Cash & Equivalents32933689.863.50
Total Debt45.91--1.40
Net Cash / Debt28333689.862.10
Book Value29931186.41-16.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Orchard Therapeutics PLC
Country United Kingdom
Employees 252
CEO Bobby Gaspar

Stock Information

Ticker Symbol ORTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ORTX
IPO Date October 31, 2018


Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type MPS-IIIA and OTL-202 for mucopolysaccharidosis type IIIB. Orchard Therapeutics plc entered into a manufacturing and technology development agreement with MolMed S.p.A. to develop, manufacture and supply certain viral vectors and conduct cell processing activities for certain Orchard development and commercial programs. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is based in London, the United Kingdom.